A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer

Key facts

Sponsor

Fudan University

Principal Investigator

Xiao-Long Fu, M.D, Ph.D.

Fudan University

Intervention

enlarge irradiation volume(radiation)

Enrollment

300 target

Eligibility

18-70 years · All sexes

Timeline

2011

Study locations (1)

• Fudan University Cancer Center, Shanghai, Shanghai Municipality, China

Collaborators

The First Affiliated Hospital of Soochow University · The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China · Jiangsu Cancer Institute & Hospital · Affiliated Hospital of Jiangsu University · Zhejiang Cancer Hospital · First Affiliated Hospital of Wenzhou Medical University · Zhejiang University · The First Affiliated Hospital of Anhui Medical University · Anhui Provincial Hospital · Fujian Cancer Hospital · Shanghai Chest Hospital · Shanghai Pulmonary Hospital, Shanghai, China · RenJi Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the esophagus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07457528
  Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07331155
  A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
  Nanjing Leads Biolabs Co.,Ltd
• RECRUITINGPHASE1NCT07503808
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07403136
  Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT07385001
  A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
  Tang-Du Hospital
• RECRUITINGPHASE2NCT07263919
  Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
  Akeso
• RECRUITINGPHASE2NCT07481058
  KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
  Beijing Konruns Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT07217171
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  EvolveImmune United, Inc

See all trials for Squamous cell carcinoma of the esophagus →